

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/568,765
Filing Date	February 21, 2006
First Named Inventor	Long Dang et al.
Art Unit	1651
Examiner Name	TBD
Attorney Docket Number	001107.00591

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 2003/045131	06-05-2003	Spampinato		
		WO 2005/039491	05-06-2005	Long		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		D. LONG ET AL., "Combination Bacteriolytic Therapy for the Treatment of Experimental Tumors," Proceedings of the National Academy of Sciences of USA, December 18, 2001; Vol. 98, No. 26, pp. 15155-15160	
		J. THEYS ET AL., "Improvement of Clostridium Tumor Targeting Vectors Evaluated in Rat Rhabdomyosarcomas," FEMS Immunology and Medical Microbiology, February 1, 2001, Vol. 30, No. 1, pp. 37-41	
		N.P. MINTON ET AL., "Clostridia in Cancer Therapy," Clostridia Biotechnology and Medical Applications, February 15, 2001, pp. 251-270	
		T. FOJO ET AL., "Taxol and Other Microtubule-Interactive Agents," Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs, January 1, 2001, Vol. 2, No. 3, pp. 293-304	
		R. F. SERVICE, "Chemical Synthesis: Tumor-Killer Made: How Does it Work?" Science, December 20, 1996, Vol. 274, No. 5295, pp. 2009	
		F. VALERIOTE ET AL., "Synergistic Interaction of Anticancer Agents: A Cellular Perspective," Cancer Chemotherapy Reports, September 1, 1975, Vol. 59, No. 5, pp. 895-900	
		D. LONG ET AL., "Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-Microtubule Agents," Cancer Biology & Therapy, March 2004, Vol. 3, No. 3, pp. 326-337	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.